DEURLE, BELGIUM--(Marketwire - February 19, 2010) - Remedent, Inc. (OTCBB: REMI), an international company specializing in the research, development, and manufacturing of oral care and cosmetic dentistry products, announced the current information for the replay of the conference call held on February 18, 2010.
Teleconference Replay Information
A telephone replay of the call is available until March 17, 2010.
Toll-free replay number: 1-800-839-5490
International replay number: 1-402-220-2550
(No passcode required)
About Remedent
Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and cosmetic dentistry products. The company serves professional dental industry with breakthrough technology for dental veneers, bridges and crowns that are recognized worldwide for their technological superiority and ease-of-application. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to www.remedent.com.
Statement under the Private Securities Litigation Reform Act of 1995
Statements in this press release that are "forward-looking statements" are
based on current expectations and assumptions that are subject to risks and
uncertainties. Such forward-looking statements involve known and unknown
risks, uncertainties and other unknown factors that could cause Remedent's
actual operating results to be materially different from any historical
results or from any future results expressed or implied by such
forward-looking statements. In addition to statements that explicitly
describe these risks and uncertainties, readers are urged to consider
statements that contain terms such as "believes," "belief," "expects,"
"expect," "intends," "intend," "anticipate," "anticipates," "plans,"
"plan," "projects," "project," to be uncertain and forward-looking. Actual
results may differ materially because of such risks and uncertainties and
the reported results should not be considered as an indication of future
performance. For further information regarding risks and uncertainties
associated with Remedent's business, please refer to the risk factors
described in Remedent's filings with the Securities and Exchange
Commission, including, but not limited to, its annual report on Form 10-K
and quarterly reports on Form 10-Q.
